Galena SEC investigation should not affect value of assets, says Maxim Maxim sees the worst case scenario from the SEC's investigation into Galena's stock promotion practices as the agency finding some liability with management. The firm says such an outcome should not materially affect the value of the company's underlying assets and it keeps a Buy rating on the stock with an $11 price target.
Galena receives notice of allowance of U.S. patent for NeuVax Galena Biopharma announced the United States Patent Office issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax. NeuVax is a peptide immunotherapy currently being evaluated for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. This patent will expand both the protection and the potential population of cancer patients NeuVax may address. Once issued, the patent will expire in 2028, not including any patent term extensions.